A practical tirzepatide guide: evidence, eligibility and what the research actually shows

The trial that shaped everything: what SURMOUNT-1 actually found

Most discussions of tirzepatide start with its mechanism, but the more useful starting point is the evidence that convinced regulators. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight and at least one weight-related condition, none of whom had type 2 diabetes. Over 72 weeks, participants taking the highest dose saw average weight reductions of around 20–21%, with some analyses reaching roughly 22.5%, figures that had not been seen in a licensed injectable weight-management medicine before. Participants taking lower doses also saw meaningful reductions, which matters because not everyone tolerates or needs the maximum.

What the raw percentages don't show is the real-world picture. Weight loss of that magnitude, sustained over more than a year, was accompanied by improvements in blood pressure, waist circumference and metabolic markers in the trial population. That context helps explain why NICE, after reviewing the full evidence package, recommended tirzepatide for NHS use in Technology Appraisal TA1026, published in December 2024.

Later, in the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. That comparison is between averages across groups; individual results vary, and a prescriber is the right person to weigh which medicine fits your circumstances.

How tirzepatide works, and why the dual mechanism matters

Tirzepatide binds to receptors for two hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are released naturally after eating. GLP-1 slows the rate at which the stomach empties and signals fullness to the brain; GIP plays a complementary role in energy metabolism. Activating both pathways together appears to produce a stronger appetite-reduction effect than activating GLP-1 alone, which is what earlier injectable medicines do.

The practical result, for most people, is a noticeable reduction in hunger between meals and a lower appetite at mealtimes. Food feels satisfying sooner. That shift makes sticking to a reduced-calorie diet less of an effort of will, which is one reason the trial results look the way they do. The NHS medicines page for tirzepatide explains the mechanism and the common side effects in plain language, and it is worth spending a few minutes reading it before starting treatment, or before your consultation, if you want to arrive with informed questions.

Tirzepatide is a Black Triangle medicine in the UK, meaning the MHRA is collecting additional safety data as it is used more widely. That is standard for newer medicines and does not indicate an unusual safety concern, but it does mean you can contribute: if you notice any side effect, you can report it at the MHRA's Yellow Card scheme.

Who tirzepatide is licensed for, and what the NICE thresholds mean in practice

The UK licence covers adults with a BMI of 30 or above, or 27 or above if they have at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or prediabetes. BMI is the threshold, but it is not the whole picture; a prescriber also considers your medical history, any medicines you currently take and whether there are contraindications before issuing a prescription.

NICE's TA1026 sets a higher bar for NHS prescribing: a BMI of 35 or above alongside at least one qualifying comorbidity. Thresholds are reduced by 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, in line with evidence that health risks associated with excess weight arise at lower BMIs in these groups. If you are wondering whether you fall within these criteria, the NHS BMI calculator takes about 30 seconds to use.

The NHS rollout is phased (eligibility is expanding gradually by cohort through 2025 to 2027) and not every GP practice is participating yet. Private treatment through a regulated online pharmacy like Mounjaro from nume means no referral, no waiting list and a same-day clinical review, subject to a prescriber confirming you are suitable. The cost context for private treatment is worth understanding before you start; our Mounjaro cost page explains what typical private pricing includes and what it doesn't.

Side effects and what to do about them

The side-effect profile of tirzepatide is led by the gastrointestinal system. Nausea is the most commonly reported, followed by constipation, diarrhoea, indigestion and burping. These effects are most noticeable after starting treatment or after a dose increase, and they generally settle within a few days to a couple of weeks as the body adapts. The slow titration schedule (starting at 2.5mg and moving up only when your prescriber judges it appropriate) exists partly to reduce the likelihood of severe GI symptoms.

Staying well hydrated helps. So does eating slowly and avoiding very fatty or heavily seasoned foods, particularly in the early weeks. If symptoms are persistent or severe rather than a mild adjustment period, that is a conversation for your prescriber, not something to manage alone.

Two things warrant urgent medical attention rather than a watchful wait. First, severe stomach pain that radiates towards the back, especially if accompanied by vomiting, can be a sign of pancreatitis, the MHRA highlighted this in a January 2026 Drug Safety Update. Second, symptoms of a serious allergic reaction (swelling of the face, throat or tongue; difficulty breathing) need emergency care. A detailed breakdown of the tirzepatide dosing journey, including how to handle a dose increase, is covered in our tirzepatide dosing guide. For general practical questions about living with treatment, our Mounjaro user guide is a helpful next read, and if you want broader context before you begin, our Mounjaro guide covers everything from how the medicine works to what to expect across each stage of treatment, while our tirzepatide page goes into further detail on the clinical background and how it compares with other options.

If you are ready to find out whether tirzepatide is clinically appropriate for you, start your free consultation with our GPhC-registered prescribers, a real clinician reviews your answers the same day, without the need for a referral or a wait.